← Leaderboards
Izabela Tworowska
Radiomedix, Inc.
$4,442,013
Attributed
$4,442,013
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2014–22$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,442,013 · 4
By mechanism
R44$1,999,943 · 1
N01$1,994,002 · 1
N43$298,132 · 1
R43$149,936 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisSmall Business Innovation Research GrantDoseDosimetryLabelRadionuclide TherapyPropertyOrganPeptide ReceptorNeuroendocrine TumorsNormal Tissue MorphologySomatostatin AnalogPharmaceutical PreparationsProductionIn Complete RemissionResponseClinical ResearchTumorInvestmentsProtocols DocumentationContractsInnovationCohortFunding
Grant awards (5)
Targeted alpha-emitter therapy of patients with PRRT refractory neuroendocrine tumors$1,451,761
R44 · FY2022 · CA · contact PI
Targeted alpha-emitter therapy of patients with PRRT refractory neuroendocrine tumors$548,182
R44 · FY2021 · CA · contact PI
IGF::OT::IGFNCI SBIR Phase II Topic 346: Molecularly Targeted Radiation Therapy for Cancer TreatmentTitle: Targeted Radionuclide Therapy of Neuroendocrine Tumors using 212Pb-octreotate Analogs$1,994,002
N01 · FY2018 · CA · contact PI
IGF::OT::IGF TARGETED RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS USING PB212-OCTREOTATE ANALOGS$298,132
N43 · FY2016 · CA · contact PI
Targeted Theranostics for Metastatic Melanoma$149,936
R43 · FY2014 · CA · contact PI